Drugs / ZE46-0134
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06366789 | May 2024 → Jan 2026 overdue | acute myeloid leukemia | Lomond Therapeutics Holdings, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06399315 | Jul 2023 → Jun 2025 | acute myeloid leukemia | Lomond Therapeutics Holdings, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03013998 | Nov 2016 → Dec 2028 expected | acute myeloid leukemia | Beat AML, LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZE46-0134 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06399315 ↗ |
| Route | Oral | “10 mg to 100 mg oral on Days 1-28 of each 28-day cycle” NCT03013998 ↗ |